Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Single Arm Clinical Study to Evaluate the Efficacy and Safety of Intratumoral Administration of BO-112 in Combination With Pembrolizumab in Subjects That Have Progressed on Anti-PD-1-based Therapy for Stage III or IV Melanoma

NCT04570332 is registered in ClinicalTrials.gov with Highlight Therapeutics as lead sponsor.

NCT NCT04570332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04570332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Single Arm Clinical Study to Evaluate the Efficacy and Safety of Intratumoral Administration of BO-112 in Combination With Pembrolizumab in Subjects That Have Progressed on Anti-PD-1-based Therapy for Stage III or IV Melanoma
Lead sponsor
Highlight Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 30, 2020
Completion date
November 4, 2024
Enrollment
42 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma